Skip to content

A prospective randomized controlled trial of laparoscopic assisted proximal gastrectomy with double tract anastomosis in less than 40 mm in diameter Siewert II and III adenocarcinomas of gastroesophageal junction

A prospective randomized controlled trial of laparoscopic assisted proximal gastrectomy with double tract anastomosis in less than 40 mm in diameter Siewert II and III adenocarcinomas of gastroesophageal junction

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000029614
Enrollment
Unknown
Registered
2020-02-07
Start date
2020-02-01
Completion date
Unknown
Last updated
2020-02-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

adenocarcinomas of gastroesophageal junction

Interventions

experimental group:proximal gastrectomy and double tract
control group:Roux-en-Y reconstruction

Sponsors

Henan Tumor Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Preoperative endoscopy and biopsy confirmed adenocarcinomas of gastroesophageal junction, and less than 40 mm in diameter predictively proximal gastrectomy; 2. Predictively resectable diseases, either early or locally advanced gastric cancer; 3. Aged 18 to 80 years; 4. Patients without previous history of upper abdominal surgery; 5. WHO performance score < 2, ASA 3; 6. Male and female; 7. Informed consent required.

Exclusion criteria

Exclusion criteria: 1. Patients is feasible for endoscopic resection; 2. Patients suffering from malignant diseases before the study; 3. Patients with other severe complications cannot tolerate surgery: such as severe heart and lung diseases, heart function below clinical stage 2, uncontrollable hypertension, pulmonary infection, moderate to severe COPD, chronic bronchitis, severe diabetes and / or renal insufficiency, severe hepatitis and / or function below the rank of CHILD B grade, and severe malnutrition, etc.; 4. Patients treated with neoadjuvant chemotherapy or radiation therapy which might affect the efficacy observation; 5. Severity mental diseases; 6. Patients have joined in other Clinical trials and may have influence on the follow-up.

Design outcomes

Primary

MeasureTime frame
fat free mass index;

Secondary

MeasureTime frame
progress free survival;overall survival;

Countries

China

Contacts

Public ContactBin Zhang

Henan Tumor Hospital

binzhang666@126.com+86 13523585968

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026